Table 2 Comparison of 3 biomarkers: RF, CCP antibodies, and 14–3-3η
From: Prevalence and significance of serum 14–3-3η in juvenile idiopathic arthritis
Biomarker | PJIA RF+ n = 39 | PJIA RF- n = 39 | ERA n = 18 | PsA n = 19 | OJIA n = 36 | Total n = 151 |
|---|---|---|---|---|---|---|
Positive 14–3-3η | 19 (49%) | 3 (8%) | 2 (11%) | 2 (11%) | 8 (22%) | 34 (23%) |
Positive 14–3-3η without RF, CCP | 0 (0%) | 1 (3%) | 2 (11%) | 2 (11%) | 7 (19%) | 12 (8%) |
Positive CCP | 30 (77%) | 4 (10%) | 0 (0%) | 0 (0%) | 2 (6%) | 36 (24%) |
Positive 14–3-3η, CCP | 16 (41%) | 2 (5%) | 0 (0%) | 0 (0%) | 1 (3%) | 19 (13%) |
Positive RF | 39 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 39 (26%) |
Positive 14–3-3η, RF | 19 (49%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 19 (13%) |
Positive 14–3-3η, RF, CCP | 16 (41%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 16 (11%)# |
Positive ANA | 20 (51%) | 15 (38%) | 10 (56%) | 10 (56%) | 23 (64%) | 78 (52%) |
Positive HLA-B27 | 2/38 (5%)a | 2/37 (5%)a | 6 (33%) | 2 (11%) | 2 (6%) | 14/148 (9%)a |